[Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
The essence of pharmacogenetic studies is to provide a scientific explanation for personal differences in the process of drugs metabolism. Polymorphism of drugs biotransformation is clinically significant from the point of view of the effectiveness and safety of pharmacotherapy and an increased risk of some illnesses. The paper presents molecular mechanisms and clinical implication of several genetic polymorphisms of cytochrome P-450 (CYP) xenobiotics metabolizing enzymes and genetic predisposition to the occurrence of some diseases.